Systemic hypertension and LVSD are the most commonly reported CVAEs in clinical trials, and their incidence is higher with the use of combination BRAF inhibitor/MEK inhibitor therapy compared with BRAF inhibitor monotherapy. This evidence concerns the gene MAP2K7 and Hypertension.